153 related articles for article (PubMed ID: 25032749)
1. ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy.
Fang S; Wu L; Li M; Yi H; Gao G; Sheng Z; Gong P; Ma Y; Cai L
Nanoscale; 2014 Sep; 6(17):10084-94. PubMed ID: 25032749
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line.
Ren J; Chen Y; Song H; Chen L; Wang R
J Cell Biochem; 2013 Jun; 114(6):1395-403. PubMed ID: 23255418
[TBL] [Abstract][Full Text] [Related]
4. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ZNF746 suppresses invasion and epithelial to mesenchymal transition in H460 non-small cell lung cancer cells.
Kim B; Sohn EJ; Jung JH; Shin EA; You OH; Im J; Kim SH
Oncol Rep; 2014 Jan; 31(1):73-8. PubMed ID: 24145959
[TBL] [Abstract][Full Text] [Related]
6. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells.
Preca BT; Bajdak K; Mock K; Sundararajan V; Pfannstiel J; Maurer J; Wellner U; Hopt UT; Brummer T; Brabletz S; Brabletz T; Stemmler MP
Int J Cancer; 2015 Dec; 137(11):2566-77. PubMed ID: 26077342
[TBL] [Abstract][Full Text] [Related]
7. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable polymeric micelle-encapsulated doxorubicin suppresses tumor metastasis by killing circulating tumor cells.
Deng S; Wu Q; Zhao Y; Zheng X; Wu N; Pang J; Li X; Bi C; Liu X; Yang L; Liu L; Su W; Wei Y; Gong C
Nanoscale; 2015 Mar; 7(12):5270-80. PubMed ID: 25721713
[TBL] [Abstract][Full Text] [Related]
9. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
[TBL] [Abstract][Full Text] [Related]
10. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
[TBL] [Abstract][Full Text] [Related]
11. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness.
Wu K; Ning Z; Zeng J; Fan J; Zhou J; Zhang T; Zhang L; Chen Y; Gao Y; Wang B; Guo P; Li L; Wang X; He D
Cell Signal; 2013 Dec; 25(12):2625-33. PubMed ID: 24012496
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment.
Liu X; Zhou XQ; Shang XW; Wang L; Li Y; Yuan H; Hu FQ
J Zhejiang Univ Sci B; 2020 Mar; 21(3):218-233. PubMed ID: 32133799
[TBL] [Abstract][Full Text] [Related]
14. Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells.
Roy BC; Kohno T; Iwakawa R; Moriguchi T; Kiyono T; Morishita K; Sanchez-Cespedes M; Akiyama T; Yokota J
Lung Cancer; 2010 Nov; 70(2):136-45. PubMed ID: 20207041
[TBL] [Abstract][Full Text] [Related]
15. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
[TBL] [Abstract][Full Text] [Related]
17. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
18. IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation.
Li Y; Wang L; Pappan L; Galliher-Beckley A; Shi J
Mol Cancer; 2012 Nov; 11():87. PubMed ID: 23174018
[TBL] [Abstract][Full Text] [Related]
19. ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH.
Zheng G; Peng C; Jia X; Gu Y; Zhang Z; Deng Y; Wang C; Li N; Yin J; Liu X; Lu M; Tang H; He Z
Mol Cancer; 2015 Apr; 14():84. PubMed ID: 25890268
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.
Werden SJ; Sphyris N; Sarkar TR; Paranjape AN; LaBaff AM; Taube JH; Hollier BG; Ramirez-Peña EQ; Soundararajan R; den Hollander P; Powell E; Echeverria GV; Miura N; Chang JT; Piwnica-Worms H; Rosen JM; Mani SA
Oncogene; 2016 Nov; 35(46):5977-5988. PubMed ID: 27292262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
